Design Therapeutics Stock News

Design Therapeutics, Inc. (NASDAQ:DSGN)s stock price traded up 4.8% during mid-day trading on Monday . The stock traded as high as $18.38 and last traded at $18.38. 722 shares traded hands during mid-day trading, a decline of 99% from the average session volume of 133,707 shares. The stock had previously closed at $17.54. Separately, Zacks []

Design Therapeutics, Inc. (NASDAQ:DSGN) saw a large increase in short interest in the month of November. As of November 15th, there was short interest totalling 1,930,000 shares, an increase of 38.8% from the October 31st total of 1,390,000 shares. Currently, 6.8% of the shares of the stock are sold short. Based on an average trading []

Design Therapeutics, Inc. (NASDAQ:DSGN) traded down 11.5% during trading on Tuesday . The stock traded as low as $17.83 and last traded at $17.98. 3,571 shares were traded during mid-day trading, a decline of 97% from the average session volume of 130,965 shares. The stock had previously closed at $20.31. Separately, Zacks Investment Research downgraded []

Design Therapeutics, Inc. (NASDAQ:DSGN) Stock analysts at SVB Leerink reduced their FY2021 earnings per share (EPS) estimates for Design Therapeutics in a research report issued on Tuesday, November 9th. SVB Leerink analyst J. Schwartz now forecasts that the company will earn ($0.80) per share for the year, down from their previous forecast of ($0.69). []

Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference Data to be Presented during the 2021 Virtual Myotonic Dystrophy Foundation Annual Conference

When insiders purchase shares, it indicates their confidence in the company's prospects or that they view the stock as a bargain. Either way, this signals an opportunity to go long on the stock.

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that Joã

CARLSBAD, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced the appo

CARLSBAD, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN) (“Design”), a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small

The stock price of Design Therapeutics Inc (NASDAQ: DSGN) has increased by 107.45% in its market debut. These are the details.

CARLSBAD, Calif., March 25, 2021 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc., a biotechnology company developing a platform of gene targeted chimera (GeneTAC™) small molecules for the treatment of

Design Therapeutics has filed proposed terms for a $228 million IPO. The firm is developing treatments for Friedreich ataxia and myotonic dystrophy.